

## [Supplemental Approvals](#)

### Generic Name (Trade Name—Company)

September 11, 2018

### Riluzole oral suspension

*(Tiglutik—ITF Pharma)*

**First easy-to-swallow riluzole liquid approved for treatment of ALS**

### Uses/Notes

FDA has [approved](#) riluzole oral suspension for the treatment of amyotrophic lateral sclerosis (ALS). It is the first and only easy-to-swallow thickened riluzole liquid for ALS and is administered twice daily via an oral syringe.

Approval was based on bioavailability studies comparing oral riluzole tablets to riluzole oral suspension. While riluzole's mechanism of action is not fully understood, in clinical studies it has been shown repeatedly to modulate glutamate neurotransmission by inhibiting both glutamate release and postsynaptic glutamate receptor signaling.

The most common adverse effects of the oral suspension are consistent with the established clinical profile of riluzole and include oral hypoesthesia, asthenia, nausea, decreased lung function, hypertension, and abdominal pain.

Riluzole oral suspension has received orphan drug designation from FDA. The product will be available in mid-October.

### Source URL:

<http://www.aphanet.org/supplemental-approvals/first-easy-swallow-riluzole-liquid-approved-treatment-als>

A<sup>PhA</sup> DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in A<sup>PhA</sup> DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of A<sup>PhA</sup>. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in A<sup>PhA</sup> DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.